← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2013First marketed drug
Dec 12, 2022First NDA
Dec 12, 2022Last known activity
Apr 30, 2025
Acquired by Bristol-Myers Squibb on Oct 9, 2023
Timeline
2010s
- Jun 1, 2013
Mirati Therapeutics Inc.— Founded
- Jun 28, 2013
MethylGene Inc.— Acquired
2020s
- Dec 12, 2022
adagrasib— Marketing Organization
- Dec 12, 2022
adagrasib— NDA Organization
- Dec 12, 2022
adagrasib— NDA Secondary Org
- Oct 9, 2023
Bristol-Myers Squibb— Acquired By
Drugs by trial phase (47 distinct, 72 trials)
Phase 3 (14 own, 1 via acquisition)
Phase 2 (9 own, 6 via acquisition)
Phase 1 (16 own, 1 via acquisition)
Indications
Studied for
- Breast Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Hodgkin Disease
- Kidney Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Liposarcoma
- Lung Neoplasms
- Lymphoma
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Mouth Neoplasms
- Myelodysplastic Syndromes
- Neoplasm Metastasis
- Neoplasms
- Preleukemia
- Prostatic Neoplasms
- Rhabdomyosarcoma
- Sarcoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
- Syndrome
- Triple Negative Breast Neoplasms
- Urinary Bladder Neoplasms
Marketed drugs (1)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT05162443Lead sponsorN/A—
- NCT06875310Lead sponsorPhase 3Apr 30, 2025
- NCT06801418Lead sponsorPhase 1Feb 4, 2025
- NCT05848843CollaboratorPhase 1Oct 30, 2024
- NCT06248606CollaboratorPhase 2Aug 6, 2024
- NCT06130254CollaboratorPhase 1May 31, 2024
- NCT06039384CollaboratorPhase 1Jan 10, 2024
- NCT05722327CollaboratorPhase 1Dec 6, 2023
- NCT05840510Lead sponsorPhase 1/Phase 2Aug 7, 2023
- NCT05840510Study directorPhase 1/Phase 2Aug 7, 2023
- NCT05924152Lead sponsorPhase 1Jun 29, 2023
- NCT05673187CollaboratorPhase 2Jun 12, 2023
- NCT05853575Study directorPhase 2Apr 5, 2023
- NCT05853575Lead sponsorPhase 2Apr 5, 2023
- NCT05634525CollaboratorPhase 1Mar 31, 2023
Details
- Founded
- San Diego, CA, US Jun 1, 2013
- First NDA
- Dec 12, 2022
- Last known activity
- Apr 30, 2025
Designations held
- Orphan drug
- Fast track
- Breakthrough therapy
- Accelerated approval